Precision medicine lead

Persona 05 / 05

— A scene from a molecular tumor board

The precision-medicine lead with a refractory patient and the wrong shelf.

Runs the molecular tumor board at an academic medical center, or the precision-medicine arm of a specialty clinic. Has the patient's full genomic profile, the prior-line history, the clinical context. The standard-of-care shelf is exhausted; the question is what to do next, at the molecular level, on a timeline measured in weeks.

“

For this patient with this mutation profile, what is the best-ranked therapeutic in the known space — and if nothing fits, what analog should we propose for compassionate-use synthesis?

— a question that arrives at the tumor board with weeks, not quarters, on the clock

What Brioche delivers

A patient-context therapeutic read. The same engine that runs against a regulatory question or a discovery question now runs against a patient-context intent — ranking the entire known therapeutic space against the patient's specific mutation landscape, then escalating to analog or novel design when the known space falls short.

Tier 01 · Re-rank Score the entire known therapeutic space — approved drugs, clinical-stage compounds, literature analogs — against the patient's specific target conformation and clinical context. Hours, not months.
Tier 02 · Analog When the known space falls short, propose minimal-modification analogs of the closest scaffold, with predicted profile and a synthesis route ready for a compassionate-use partner.
Tier 03 · Novel When no precedent fits, generate novel matter against the patient's target — the same workflow downstream engagements consume, scoped per case.
Format A written tumor-board memo with cited primary sources, predicted-profile rationale, and a regulatory-pathway note: investigator-initiated IND, expanded access, milasen-class precedent. Reviewer-signed.

Illustrative scenario · not a real engagement Scenario sketch

A refractory patient with a rare driver mutation; standard of care exhausted; the molecular tumor board has weeks to recommend a path.

Genomic diagnostics tell the board what is wrong. The brief Brioche writes back tells them what to do about it at the molecular level — ranked existing therapy first, analog if the shelf falls short, novel design if neither fits. One sells data. The other sells decisions.

— Track 01

Re-rank the known space. Every approved drug, clinical-stage compound, and literature analog scored against the patient's specific target conformation and prior-line history. Top candidates surfaced with mechanistic rationale and predicted-profile evidence.

— Track 02

Escalate to analog. Where the known space falls short, propose minimal-modification analogs of the closest scaffold — predicted potency, selectivity, ADMET red flags, synthesis route. Hand-off package for compassionate-use synthesis partner.

— Track 03

Regulatory pathway note. The investigator-initiated IND or expanded-access framework that fits the case, with the milasen-class precedent cited where applicable. Pathway exists; the brief makes it usable.

The precision-medicine lead with a refractory patient and the wrong shelf.

What Brioche delivers

A refractory patient with a rare driver mutation; standard of care exhausted; the molecular tumor board has weeks to recommend a path.

How other teams use Brioche.